Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6

Aiming Yu, Jeffrey R. Idle, Linda G. Byrd, Kristopher W. Krausz, Adrian Küpfer, Frank J. Gonzalez

Research output: Contribution to journalArticle

147 Citations (Scopus)

Abstract

Polymorphic cytochrome P450 2D6 (CYP2D6) is expressed in several types of central neurons but its function in human brain is currently unknown. Using recombinant enzymes and CYP2D6-transgenic mice, we established that 5-methoxytryptamine (5-MT), a metabolite and precursor of melatonin, is a specific and high-turnover endogenous substrate of CYP2D6. This potent serotonergic neuromodulator in numerous physiological systems binds tightly to recombinant CYP2D6 enzyme with an equilibrium dissociation constant (Ks) of 23.4 μmol/l, and is O-demethylated to serotonin (5-hydroxytryptamine, 5-HT) with a high turnover of 51.7 min-1 and low Michaelis-Menten constant of 19.5 μmol/l. The production of 5-HT from 5-MT catalyzed by CYP2D6 was inhibited by selective serotonin reuptake inhibitors, and their inhibition potency (Ki, μmol/l) decreased in the order of fluoxetine (0.411 ) > norfluoxetine (1.38) > fluvoxamine (10.1) > citalopram (10.9). Liver microsomes prepared from CYP2D6-transgenic mice showed about 16-fold higher 5-MT O-demethylase activity than that from wild-type mice. After the intravenous co-administration of 5-MT (10 mg/kg) and pargyline (20 mg/kg), serum 5-HT level was about 3-fold higher in CYP2D6-transgenic mice than wild-type mice. When dosed with α,α,β,β-d4-5-MT, α,α,β,β-d4-5-HT was detected in CYP2D6 transgenic mouse serum, and its content was much higher than wild-type mouse, α,α,β,β-d4-5-HT was not produced in CYP2D6-transgenic mice pretreated with quinidine. The regeneration of 5-HT from 5-MT provides the missing link in the serotonin-melatonin cycle. Up to 10% of the population lacks this enzyme. It is proposed that this common inborn error in 5-MT O-demethylation to serotonin influences a range of neurophysiologic and pathophysiologic events.

Original languageEnglish (US)
Pages (from-to)173-181
Number of pages9
JournalPharmacogenetics
Volume13
Issue number3
DOIs
StatePublished - Mar 2003
Externally publishedYes

Fingerprint

5-Methoxytryptamine
Cytochrome P-450 CYP2D6
Regeneration
Serotonin
Transgenic Mice
Melatonin
O Demethylating Oxidoreductases
Pargyline
Fluvoxamine
Citalopram
Quinidine
Fluoxetine
Serotonin Uptake Inhibitors
Liver Microsomes
Enzymes
Serum
Intravenous Administration
Cytochrome P-450 Enzyme System
Neurotransmitter Agents

Keywords

  • 5-Hydroxytryptamine
  • 5-Methoxytryptamine
  • CYP2D6
  • Melatonin

ASJC Scopus subject areas

  • Genetics
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Yu, A., Idle, J. R., Byrd, L. G., Krausz, K. W., Küpfer, A., & Gonzalez, F. J. (2003). Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics, 13(3), 173-181. https://doi.org/10.1097/00008571-200303000-00007

Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. / Yu, Aiming; Idle, Jeffrey R.; Byrd, Linda G.; Krausz, Kristopher W.; Küpfer, Adrian; Gonzalez, Frank J.

In: Pharmacogenetics, Vol. 13, No. 3, 03.2003, p. 173-181.

Research output: Contribution to journalArticle

Yu, A, Idle, JR, Byrd, LG, Krausz, KW, Küpfer, A & Gonzalez, FJ 2003, 'Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6', Pharmacogenetics, vol. 13, no. 3, pp. 173-181. https://doi.org/10.1097/00008571-200303000-00007
Yu, Aiming ; Idle, Jeffrey R. ; Byrd, Linda G. ; Krausz, Kristopher W. ; Küpfer, Adrian ; Gonzalez, Frank J. / Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. In: Pharmacogenetics. 2003 ; Vol. 13, No. 3. pp. 173-181.
@article{b40ee2883883434fb509cd64cbcc1727,
title = "Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6",
abstract = "Polymorphic cytochrome P450 2D6 (CYP2D6) is expressed in several types of central neurons but its function in human brain is currently unknown. Using recombinant enzymes and CYP2D6-transgenic mice, we established that 5-methoxytryptamine (5-MT), a metabolite and precursor of melatonin, is a specific and high-turnover endogenous substrate of CYP2D6. This potent serotonergic neuromodulator in numerous physiological systems binds tightly to recombinant CYP2D6 enzyme with an equilibrium dissociation constant (Ks) of 23.4 μmol/l, and is O-demethylated to serotonin (5-hydroxytryptamine, 5-HT) with a high turnover of 51.7 min-1 and low Michaelis-Menten constant of 19.5 μmol/l. The production of 5-HT from 5-MT catalyzed by CYP2D6 was inhibited by selective serotonin reuptake inhibitors, and their inhibition potency (Ki, μmol/l) decreased in the order of fluoxetine (0.411 ) > norfluoxetine (1.38) > fluvoxamine (10.1) > citalopram (10.9). Liver microsomes prepared from CYP2D6-transgenic mice showed about 16-fold higher 5-MT O-demethylase activity than that from wild-type mice. After the intravenous co-administration of 5-MT (10 mg/kg) and pargyline (20 mg/kg), serum 5-HT level was about 3-fold higher in CYP2D6-transgenic mice than wild-type mice. When dosed with α,α,β,β-d4-5-MT, α,α,β,β-d4-5-HT was detected in CYP2D6 transgenic mouse serum, and its content was much higher than wild-type mouse, α,α,β,β-d4-5-HT was not produced in CYP2D6-transgenic mice pretreated with quinidine. The regeneration of 5-HT from 5-MT provides the missing link in the serotonin-melatonin cycle. Up to 10{\%} of the population lacks this enzyme. It is proposed that this common inborn error in 5-MT O-demethylation to serotonin influences a range of neurophysiologic and pathophysiologic events.",
keywords = "5-Hydroxytryptamine, 5-Methoxytryptamine, CYP2D6, Melatonin",
author = "Aiming Yu and Idle, {Jeffrey R.} and Byrd, {Linda G.} and Krausz, {Kristopher W.} and Adrian K{\"u}pfer and Gonzalez, {Frank J.}",
year = "2003",
month = "3",
doi = "10.1097/00008571-200303000-00007",
language = "English (US)",
volume = "13",
pages = "173--181",
journal = "Pharmacogenetics and Genomics",
issn = "1744-6872",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6

AU - Yu, Aiming

AU - Idle, Jeffrey R.

AU - Byrd, Linda G.

AU - Krausz, Kristopher W.

AU - Küpfer, Adrian

AU - Gonzalez, Frank J.

PY - 2003/3

Y1 - 2003/3

N2 - Polymorphic cytochrome P450 2D6 (CYP2D6) is expressed in several types of central neurons but its function in human brain is currently unknown. Using recombinant enzymes and CYP2D6-transgenic mice, we established that 5-methoxytryptamine (5-MT), a metabolite and precursor of melatonin, is a specific and high-turnover endogenous substrate of CYP2D6. This potent serotonergic neuromodulator in numerous physiological systems binds tightly to recombinant CYP2D6 enzyme with an equilibrium dissociation constant (Ks) of 23.4 μmol/l, and is O-demethylated to serotonin (5-hydroxytryptamine, 5-HT) with a high turnover of 51.7 min-1 and low Michaelis-Menten constant of 19.5 μmol/l. The production of 5-HT from 5-MT catalyzed by CYP2D6 was inhibited by selective serotonin reuptake inhibitors, and their inhibition potency (Ki, μmol/l) decreased in the order of fluoxetine (0.411 ) > norfluoxetine (1.38) > fluvoxamine (10.1) > citalopram (10.9). Liver microsomes prepared from CYP2D6-transgenic mice showed about 16-fold higher 5-MT O-demethylase activity than that from wild-type mice. After the intravenous co-administration of 5-MT (10 mg/kg) and pargyline (20 mg/kg), serum 5-HT level was about 3-fold higher in CYP2D6-transgenic mice than wild-type mice. When dosed with α,α,β,β-d4-5-MT, α,α,β,β-d4-5-HT was detected in CYP2D6 transgenic mouse serum, and its content was much higher than wild-type mouse, α,α,β,β-d4-5-HT was not produced in CYP2D6-transgenic mice pretreated with quinidine. The regeneration of 5-HT from 5-MT provides the missing link in the serotonin-melatonin cycle. Up to 10% of the population lacks this enzyme. It is proposed that this common inborn error in 5-MT O-demethylation to serotonin influences a range of neurophysiologic and pathophysiologic events.

AB - Polymorphic cytochrome P450 2D6 (CYP2D6) is expressed in several types of central neurons but its function in human brain is currently unknown. Using recombinant enzymes and CYP2D6-transgenic mice, we established that 5-methoxytryptamine (5-MT), a metabolite and precursor of melatonin, is a specific and high-turnover endogenous substrate of CYP2D6. This potent serotonergic neuromodulator in numerous physiological systems binds tightly to recombinant CYP2D6 enzyme with an equilibrium dissociation constant (Ks) of 23.4 μmol/l, and is O-demethylated to serotonin (5-hydroxytryptamine, 5-HT) with a high turnover of 51.7 min-1 and low Michaelis-Menten constant of 19.5 μmol/l. The production of 5-HT from 5-MT catalyzed by CYP2D6 was inhibited by selective serotonin reuptake inhibitors, and their inhibition potency (Ki, μmol/l) decreased in the order of fluoxetine (0.411 ) > norfluoxetine (1.38) > fluvoxamine (10.1) > citalopram (10.9). Liver microsomes prepared from CYP2D6-transgenic mice showed about 16-fold higher 5-MT O-demethylase activity than that from wild-type mice. After the intravenous co-administration of 5-MT (10 mg/kg) and pargyline (20 mg/kg), serum 5-HT level was about 3-fold higher in CYP2D6-transgenic mice than wild-type mice. When dosed with α,α,β,β-d4-5-MT, α,α,β,β-d4-5-HT was detected in CYP2D6 transgenic mouse serum, and its content was much higher than wild-type mouse, α,α,β,β-d4-5-HT was not produced in CYP2D6-transgenic mice pretreated with quinidine. The regeneration of 5-HT from 5-MT provides the missing link in the serotonin-melatonin cycle. Up to 10% of the population lacks this enzyme. It is proposed that this common inborn error in 5-MT O-demethylation to serotonin influences a range of neurophysiologic and pathophysiologic events.

KW - 5-Hydroxytryptamine

KW - 5-Methoxytryptamine

KW - CYP2D6

KW - Melatonin

UR - http://www.scopus.com/inward/record.url?scp=0037342251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037342251&partnerID=8YFLogxK

U2 - 10.1097/00008571-200303000-00007

DO - 10.1097/00008571-200303000-00007

M3 - Article

C2 - 12618595

AN - SCOPUS:0037342251

VL - 13

SP - 173

EP - 181

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

SN - 1744-6872

IS - 3

ER -